<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140813</url>
  </required_header>
  <id_info>
    <org_study_id>CIN001 - AZD7325 in FXS</org_study_id>
    <nct_id>NCT03140813</nct_id>
  </id_info>
  <brief_title>An Initial Study of AZD7325 in Adults With Fragile X Syndrome</brief_title>
  <official_title>An Initial Double-Blind, Placebo-Controlled Two-Dose Crossover Study of AZD7325 in Adults With Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability and blood pharmacodynamics of treatment&#xD;
      with oral administration of AZD7325 at 5 mg BID, 15 mg BID, and placebo BID, in adults with&#xD;
      Fragile X Syndrome. The study also will also investigate measures of efficacy and biomarkers&#xD;
      during treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amyloid Precursor Protein (APP)</measure>
    <time_frame>Through end of study, approximately 12 weeks</time_frame>
    <description>Short-term treatment of peripheral APP dysregulation by correcting elevated levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)</measure>
    <time_frame>Through end of study, approximately 12 weeks</time_frame>
    <description>The ABC is the gold standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Pediatric Anxiety Rating Scale (PARS)</measure>
    <time_frame>Through end of study, approximately 12 weeks</time_frame>
    <description>The PARS is the gold standard parent/caregiver reported anxiety outcome measure for use in Fragile X Syndrome clinical trials.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo - Low-Dose - High-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - High-Dose - Low-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose - Placebo - High-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose - High-Dose - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose - Low-Dose - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose - Placebo - Low-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7325 (High-Dose)</intervention_name>
    <description>15mg PO BID</description>
    <arm_group_label>High-Dose - Low-Dose - Placebo</arm_group_label>
    <arm_group_label>High-Dose - Placebo - Low-Dose</arm_group_label>
    <arm_group_label>Low-Dose - High-Dose - Placebo</arm_group_label>
    <arm_group_label>Low-Dose - Placebo - High-Dose</arm_group_label>
    <arm_group_label>Placebo - High-Dose - Low-Dose</arm_group_label>
    <arm_group_label>Placebo - Low-Dose - High-Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7325 (Low-Dose)</intervention_name>
    <description>5mg PO BID</description>
    <arm_group_label>High-Dose - Low-Dose - Placebo</arm_group_label>
    <arm_group_label>High-Dose - Placebo - Low-Dose</arm_group_label>
    <arm_group_label>Low-Dose - High-Dose - Placebo</arm_group_label>
    <arm_group_label>Low-Dose - Placebo - High-Dose</arm_group_label>
    <arm_group_label>Placebo - High-Dose - Low-Dose</arm_group_label>
    <arm_group_label>Placebo - Low-Dose - High-Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.</description>
    <arm_group_label>High-Dose - Low-Dose - Placebo</arm_group_label>
    <arm_group_label>High-Dose - Placebo - Low-Dose</arm_group_label>
    <arm_group_label>Low-Dose - High-Dose - Placebo</arm_group_label>
    <arm_group_label>Low-Dose - Placebo - High-Dose</arm_group_label>
    <arm_group_label>Placebo - High-Dose - Low-Dose</arm_group_label>
    <arm_group_label>Placebo - Low-Dose - High-Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnostic confirmation of full mutation FXS&#xD;
&#xD;
          -  50 ≥ Age ≥18 years. Males and Females included in study.&#xD;
&#xD;
          -  General good health as determined by physical exam, medical history and laboratory&#xD;
             work up.&#xD;
&#xD;
          -  FXS genetic reports at screening&#xD;
&#xD;
          -  IQ less than or equal to 80. Note: IQ cutoff is used as a means to exclude cases of&#xD;
             females with FXS who have the full mutation, but may have neurotypical development&#xD;
             (ie: do not have the full FXS phenotype despite positive FXS genetic testing) due to&#xD;
             variability in X chromosome inactivation patterns.&#xD;
&#xD;
          -  Male study participants who are sexually active with a female partner of childbearing&#xD;
             potential must be surgically sterilized, practicing abstinence, or agree to use highly&#xD;
             effective methods of birth control (defined in the list below), and not rely on&#xD;
             barrier methods and spermicide alone, from the time of screening until 1 week after&#xD;
             final dose of study drug. Male study participants must also not donate sperm from the&#xD;
             time of screening until 1 week after final dose of study drug. Given that AZD7325 is&#xD;
             not mutagenic, there is no mandatory requirement for condom use, either for avoidance&#xD;
             of procreation or in the case of treated males with a pregnant partner.&#xD;
&#xD;
          -  Women of childbearing potential may be included in the study provided they are&#xD;
             established on, and continue to use, highly effective contraceptive methods from the&#xD;
             time of screening until 1 week after the final dose of study drug. Highly effective&#xD;
             methods of contraception associated with inhibition of ovulation (either oral,&#xD;
             intravaginal or transdermal), progestin-only hormonal contraception associated with&#xD;
             inhibition of ovulation (either oral [specifically Micronor, Nor-QD or their generic&#xD;
             equivalents], injectable or implantable).&#xD;
&#xD;
          -  Aberrant Behavior Checklist total score of 20 or higher at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant use of modulators of GABA A neurotransmission. (examples)&#xD;
&#xD;
          -  Use of more than three psychotropic drugs that do not directly impact GABA&#xD;
             transmission, and/or unstable dosing of any psychotropic medication in the 4 weeks&#xD;
             prior to baseline visit.&#xD;
&#xD;
          -  Subjects are prohibited from use of strong and moderate modulators of CYP3A and&#xD;
             CYP2C19 during the screening (at least 2 weeks before initiation of the study) and&#xD;
             treatment periods of the study. Such prohibited drugs are outlined in&#xD;
             http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/u&#xD;
             cm292362.pdf&#xD;
&#xD;
          -  CNS-suppressing agents such as central analgesics, muscle relaxants, benzodiazepines,&#xD;
             other sedatives, and should also limit alcohol intake to ≤1 alcoholic beverage per&#xD;
             day.&#xD;
&#xD;
          -  Unstable seizure disorder as defined by any seizure in the 6 months prior to baseline&#xD;
             visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study&#xD;
             entry.&#xD;
&#xD;
          -  All patients with abnormal baseline safety lab assessments including, but not limited&#xD;
             to ALT or AST greater than 1.5 the upper limit of normal, total bilirubin or&#xD;
             creatinine greater than 1 time the upper limit of normal or other clinically relevant&#xD;
             lab abnormality or abnormality in ECG, HR or BP at screening as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Clinical relevant history or presence of any medical disorder judged by the&#xD;
             investigator at potentially interfering with this trial.&#xD;
&#xD;
          -  History of or current abuse of drugs or alcohol including prescription medication.&#xD;
&#xD;
          -  For female subjects of child bearing potential (women 50 &amp; under is &quot;amenorrhoeic for&#xD;
             12 months or more (following cessation of exogenous hormonal treatments - if these&#xD;
             have been previously taken) and with luteinizing hormone (LH) and follicle stimulating&#xD;
             hormone (FSH) levels in the post-menopausal range) a positive pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest Pedapati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Chlidren's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

